COMMANDER HF trial

COMMANDER HF Trial Summary: Zannand F et al. randomized 5,022 patients with coronary artery disease and heart failure to undergo treatment with either rivaroxaban or a placebo. The primary objective of the study was to assess if rivaroxaban could reduce thrombin production and improve outcomes in patients with CAD and HF. The results showed that rivaroxaban did not affect the composite

Source: NEJM